Compare Sanofi SA (SNY) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs AT&T Inc. — how do they compare? Sanofi SA trades at $40.07 (market cap $95.18B), while AT&T Inc. trades at $22.18 (market cap $170.42B). The key difference: AT&T Inc. is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and AT&T Inc. for 118 Days on average.
| SNY | T | |
|---|---|---|
Market Cap | $95.18B | $170.42B |
Volume | 2,995,646 | 50,780,036 |
Sector | Health | Media |
52-Week High | $52.34 | $29.10 |
52-Week Low | $39.51 | $20.49 |
Typical Hold Time | 94 Days | 118 Days |
Enterprise Value | $114.48B | $315.74B |
Dividend Yield | 6.01% | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
AT&T (T) trades at $24.885, up 1.68% today, with a bullish technical signal overall despite mixed moving averages and oscillators. The company shows strong fundamentals with a P/E of 8.21, net income margin of 16.94%, and consistent earnings beats in recent quarters. Recent news highlights a $3 billion fiber deal with Corning and a joint venture with T-Mobile and Verizon to expand coverage.
The outlook is positive with a consensus price target of $27.50, offering potential upside. Key risks include high debt levels and competitive pressures. The stock presents a value opportunity with a solid dividend, but investors should monitor debt management and revenue growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
